ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $675k

      Shares

      13.9k

      % of Portfolio

      0.00%

      Average Buy Price

      $45.3

      Avg closing price
      Price range

      1 Polen Capital Hims & Hers Health Trades

      Polen Capital acquired 13.9k Hims & Hers Health shares worth $675k. That's 0.00% of their equity portfolio (168th largest holding). The stake costed the investor $632k, netting the investor a gain of 6.9% so far.

      Avg closing price
      Price range
      New holding (+13.9k shares) Q2 2025
      Avg closing price $45.28
      Price range $25.35 - $64.65

      News about Hims & Hers Health Inc - Ordinary Shares - Class A and Polen Capital

      Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)

      Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)

      I expect price sensitive consumers to flood the market for compounded GLP-1 drugs before the 60-day FDA grace period for semaglutide compounders. HIMS projec...

      seekingalpha.com seekingalpha.com, 6 months ago
      Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report

      Short Seller Hunterbrook Slams Hims & Hers (HIMS) Stock in New Report

      Hims & Hers Health (NYSE: HIMS ) stock is taking a tumble after Hunterbrook Media released a short report on the telehealth company. Hunterbrook operates an ...

      investorplace.com investorplace.com, about 1 year ago
      Hims & Hers: Market Blows Off Short Report

      Hims & Hers: Market Blows Off Short Report

      Spruce Capital Management issued a short report on Hims & Hers Health, Inc., but the call only forecast downside risk to $5. Read more about HIMS stock here.

      Seeking Alpha Seeking Alpha, about 2 years ago
      Hims & Hers Health''s Return On Capital Employed Overview

      Hims & Hers Health''s Return On Capital Employed Overview

      According to Benzinga Pro data, during Q4, Hims & Hers Health (NYSE: HIMS ) posted sales of $167.20 million. Earnings were up 42.11%, but Hims & Hers Health ...

      Benzinga Benzinga, over 2 years ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×